Insmed, Inc. $INSM Stock Holdings Raised by Darwin Global Management Ltd.

Darwin Global Management Ltd. increased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 5.8% in the third quarter, Holdings Channel.com reports. The fund owned 20,457,445 shares of the biopharmaceutical company’s stock after buying an additional 1,112,824 shares during the quarter. Insmed comprises about 80.5% of Darwin Global Management Ltd.’s portfolio, making the stock its largest holding. Darwin Global Management Ltd. owned about 0.10% of Insmed worth $2,897,797,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Savant Capital LLC purchased a new stake in Insmed in the second quarter worth $205,000. PNC Financial Services Group Inc. boosted its stake in shares of Insmed by 8.8% during the second quarter. PNC Financial Services Group Inc. now owns 11,576 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 933 shares during the period. Creative Planning grew its holdings in shares of Insmed by 0.6% in the second quarter. Creative Planning now owns 72,176 shares of the biopharmaceutical company’s stock worth $7,264,000 after purchasing an additional 432 shares during the last quarter. Cetera Investment Advisers increased its stake in Insmed by 52.1% in the 2nd quarter. Cetera Investment Advisers now owns 31,462 shares of the biopharmaceutical company’s stock worth $3,166,000 after buying an additional 10,783 shares during the period. Finally, Kingsview Wealth Management LLC bought a new stake in Insmed during the 2nd quarter valued at about $228,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Bank of America set a $203.00 price objective on shares of Insmed in a research report on Thursday, December 18th. Jefferies Financial Group set a $269.00 target price on shares of Insmed in a research report on Wednesday, December 10th. Royal Bank Of Canada lifted their price target on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Leerink Partners reissued an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Finally, Citigroup restated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $207.52.

Insmed Trading Down 0.0%

INSM opened at $139.50 on Monday. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The firm has a market cap of $30.07 billion, a price-to-earnings ratio of -21.76 and a beta of 1.13. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The stock has a fifty day moving average price of $155.18 and a 200-day moving average price of $166.16.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period in the previous year, the business earned ($1.32) EPS. Insmed’s revenue for the quarter was up 152.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Sara Bonstein sold 748 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer directly owned 79,758 shares in the company, valued at approximately $12,469,365.72. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,982,045.55. The trade was a 3.43% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 189,651 shares of company stock valued at $31,784,545. Corporate insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.